You are here:

daptomycin (Cubicin)

Advice

Following a full submission

daptomycin (Cubicin®) is accepted for restricted use within NHS Scotland for the treatment of Staphylococcus aureus bacteraemia (SAB) when associated with right-sided infective endocarditis (RIE) or with complicated skin and soft-tissue infections in adults.

Daptomycin should be restricted to use in patients with known or suspected methicillinresistant S. aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease. Daptomycin has been shown to be as effective as standard therapy in patients with S. aureus bacteraemia with or without endocarditis, though data on the subgroup of patients with RIE due to MRSA are very limited.

Daptomycin has a higher acquisition cost than some alternative treatments; it does not, however, require therapeutic drug monitoring.

Drug Details

Drug Name: daptomycin (Cubicin)
SMC Drug ID: 449/08
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: treatment of staphylococcus aureus bacteraemia (SAB) when associated with right-sided infective endocarditis or with complicated skin and soft-tissue infection in adults
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 March 2008

Back